Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (June 2023)
24 slides from Xoma Royalty's investor presentation, June 2023
Slide 1: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES JUNE 2023
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking SEC filings. Consider such risks carefully when considering XOMA's statements within the meaning of Section 27A of the Securities Act of prospects. Any forward-looking statements represent XOMA’s views 1933 and Section 21E of th
Slide 3: Opportunities Abound for Royalty Monetization
OPPORTUNITIES ABOUND FOR ROYALTY MONETIZATION License LIFE SCIENCES INDUSTRY LICENSING DEALS ANNUALLY transactions 2014 – 2021 consist of: ▪ Upfront payment 645 648 620 ▪ Milestone payments 585 522 548 ▪ Royalty obligations 459 404 2014 2015 2016 2017 2018 2019 2020 2021 Bloomberg data 3
Slide 4: We Buy
WE BUY: & 4
Slide 5: XOMA's Ideal Asset
XOMA’S IDEAL ASSET STRONG DEVELOPER/MARKETER Assets partnered with high-quality pharma / biopharma companies MID- TO EARLY-STAGE CLINICAL ASSETS Rx Therapeutic area agnostic LONG DURATION OF MARKET EXCLUSIVITY Patent expiration or regulatory exclusivity HIGH REVENUE POTENTIAL High unmet need or clea
Slide 6: Basics of a XOMA Royalty Monetization Transaction
BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION STEP 1: STEP 2: Capital BIOTECH Royalties & Milestones Program Royalties & Licensed Milestones BIG PHARMA 6
Slide 7: Actively Acquiring New Royalties
ACTIVELY ACQUIRING NEW ROYALTIES SELLER PARTNER / LICENSEE # ASSETS CAPITAL DEPLOYED THERAPEUTIC AREA or INDICATION(s) $14M Affitech 1 ($6M upfront, $5M at FDA approval, wAMD, DME, other retinal conditions $3M at EU approval) Aptevo 1 $9.6M Hemophilia B LadRx 2 $5M Niemann-Pick Type C, pancreatic ca
Slide 8: Arimoclomol + Aldoxorubicin Transaction
ARIMOCLOMOL + ALDOXORUBICIN TRANSACTION: $5M outlay to LadRx1 $396M potential milestones Mid-single to mid-teens royalties Arimoclomol will be a first-in-class therapy if approved by regulatory authorities for NPC. Zevra preparing NDA filing for arimoclomol in Niemann-Pick disease Type C (NPC) 2 Imm
Slide 9: Ixinity Transaction
IXINITY TRANSACTION: ® $9.6M outlay to Aptevo Mid-single digit royalties on sales beginning 1/1/2023 into 1Q2035 Marketed in the U.S. by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B 9
Slide 10: Ebopiprant Transaction
EBOPIPRANT TRANSACTION: $15M outlay to ObsEva $378M potential milestones Mid-single to low-teens royalty, net Organon secured development & commercialization license from ObsEva in July 2021 “This development-stage asset is being studied in one of the most crucial unmet needs for women globally. As
Slide 11: XOMA Is Differentiated in Royalty Monetization
XOMA IS DIFFERENTIATED IN ROYALTY MONETIZATION Capital per transaction $200M + Royalty Pharma $100M – DRI $200M Healthcare Trust $25M – FOCUSED ON Ligand $100M MID- TO EARLY-STAGE CLINICAL ASSETS HCRP < $25M PRECL IN ICA L PHASE 1 PHASE 2 PHASE 3 APPROVAL CO MMERCIA L 11
Slide 12: Royalty Monetization - Increasingly in Focus
ROYALTY MONETIZATION - INCREASINGLY IN FOCUS 12
Slide 13: Royalty Monetization Increasingly More Attractive
ROYALTY MONETIZATION INCREASINGLY MORE ATTRACTIVE Source: The Brookline Brief, November 2, 2022 13
Slide 14: XOMA Snapshot: 70+ Assets
XOMA SNAPSHOT Portfolio of ▪ Acquire drug royalties + milestones associated with mid- to early stage clinical candidates 70+ ASSETS – Differentiate by focusing on development-stage assets in >30 disclosed indications with blockbuster potential licensed to large-cap partners today and growing ▪ Provi
Slide 15: Key XOMA Portfolio Assets
KEY XOMA PORTFOLIO ASSETS https://www.xoma.com/portfolio 15
Slide 16: XOMA's Broad Portfolio Without Spend
XOMA’S BROAD PORTFOLIO WITHOUT SPEND COMMERCIALIZ ED PHASE 3 PHASE 2 Further Development 2 Assets 4 Assets 27 Assets Expenses by XOMA: PHASE 1/2 PHASE 1 PRECLINICAL $0 2 16 15+ >50% of assets with Large-cap partners Assets Assets Assets 16
Slide 17: Since 2017, XOMA's Portfolio Continues to Advance and Mature
SINCE 2017, XOMA’S PORTFOLIO CONTINUES TO ADVANCE AND MATURE PHASE 3 TO APPROVAL 1 PHASE 2 TO PHASE 3 4 PHASE 2A TO PHASE 2B 2 PHASE 1 TO PHASE 2 11 30 Advancements PHASE → PHASE ENTERED CLINIC 12 PRECL IN ICA L PHASE 1 PHASE 2 PHASE 3 APPROVAL 17
Slide 18: 2023: Potential Events from Our Partners
2023: POTENTIAL EVENTS FROM OUR PARTNERS S P O N S O R / PR O G RA M : Phase 1 Phase 2 Phase 3 Regulatory Medexus / IXINITY Pediatric Label Expansion filed Day One / tovorafenib Ph 2 pediatric low-grade glioma readout Ph 3 initiation NDA Filed Zevra / arimoclomol BLA Filed Rezolute / RZ358 Ph 2 comp
Slide 19: Who We Are
WHO WE ARE Board of Directors ▪ Leadership ▪ Owen Hughes, Executive Chair XOMA – Owen Hughes, Executive Chair ▪ Heather L. Franklin – Brad Sitko, Chief Investment Officer Blaze BioScience – Tom Burns, Chief Financial Officer ▪ Natasha Hernday Seagen ▪ Business Development Team ▪ Barbara Kosacz Krono
Slide 20: Financial Highlights
FINANCIAL HIGHLIGHTS ($M) $100 Y/E Cash $90 $80 Expenses >$94M $70 in milestone $60 payments $50 since 2016 $40 $30 ~$1.5B $20 in potential $10 milestones $0 2016 2017 2018 2019 2020 2021 2022 20
Slide 21: Roche's Vabysmo Approved in US, EU, Japan
Regulatory agencies in US, EU, Japan, others have granted commercialization approval to Roche’s VABYSMO® (faricimab) XOMA received >$2.9M on sales through 12/31/22 THE FIRST ASSET UNDER XOMA’S ROYALTY AGGREGATOR BUSINESS MODEL TO BE APPROVED Acquired economic rights from Affitech SA 21
Slide 22: What Makes XOMA So Exciting
WHAT MAKES XOMA SO EXCITING ▪ XOMA’s model demonstrates future potential through cash from commercial sales ‒ >$2.9M cash received from Roche’s VABYSMO®1 sales through 12/31/22 ‒ Cash from IXINITY® sales begin 1Q23 ▪ Potential royalty stream on 70+ assets; pharmaceutical partners fund 100% of resear
Slide 23: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES JUNE 2023
Slide 24: Partner-Driven Clinical Events Achieved in 2021 & 2022
A SIGNIFICANT NUMBER OF PARTNER-DRIVEN CLINICAL EVENTS ACHIEVED IN 2021 & 2022 As disclosed by partners in public filings PHASE 1 PHASE 1/2 PHASE 2 PHASE 3 REGULATORY ▪ Bayer/osocimab: ▪ Incyte/INCAGN01876: Advanced Rezolute/RZ358: ▪ Novartis/NIS793: ▪ Roche/VABYSMO® ESRD completed malignancies comp